How medicine advances

Clinical Infectious Diseases

Volumn 48, Issue 4, 2009, Pages 407-409

  Chapman, Louisa E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADENOVIRUS INFECTION; ANEMIA; ARENAVIRUS; BUNYAVIRUS; DRUG EFFICACY; DRUG SAFETY; HANTAVIRUS PULMONARY SYNDROME; HEMORRHAGIC FEVER; HEPATITIS; HEPATITIS C; HUMAN; INFLUENZA; LASSA FEVER; NONHUMAN; NOTE; PANCREATITIS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RIFT VALLEY FEVER BUNYAVIRUS;

ANTIVIRAL AGENTS; HISTORY OF MEDICINE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIRUS DISEASES;

EID: 58749098048     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596310     Document Type: Note

References (18)

1. McCullough D. John Adams. New York: Simon and Schuster Paperbacks, 2001.
2. World Health Organization. Epidemic and pandemic alert response: new virus from Arenaviride family in South Africa and Zambia - Update. 13 October 2008. Available at: http://www.who.int/csr/don/2008-10-13/en/index.html. Accessed 23 October 2008.
3. World Health Organization. Epidemic and pandemic alert response: unknown disease in South Africa and Zambia. 10 October 2008. Available at: http://www.who.int/csr/don/2008-10-10/en/index.html. Accessed 23 October 2008.
4. Cameron CE, Castro C. The mechanism of action of repairing: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis 2001; 14:757-764.
5. Committee on Infectious Diseases, American Academy of Pediatrics. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996; 97:137-40.
6. McCormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with repairing. N Engl J Med 1986; 314:20-6.
7. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164:1119-27.
8. Rusnak JM, Byrne WR, Chung KN, et al. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antivir Res 2008; 81:68-76.
9. Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for handovers pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Antivir Ther 1999; 4:211-9.
10. Chapman LE, Ellis BA, Koster TG, et al. Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome. Clin Infect Dis 2002; 34:293-304.
11. Mertz GJ, Miedzinski L, Goade D, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 2004; 39:1307-13.
12. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antivir Res 2004; 64:145-60.
13. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antivir Res 2008; 78:125-31.
14. Bour H, Erbay A, Akinci E, et al. Effect of oral ribavirin treatment to the viral load and progress of the disease in Crimean-Congo hemorrhagic fever [abstract V-1656]. In: Program and abstracts of the 48th Annual Meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy-Infectious Diseases Society of America (Washington, DC). Washington, DC: American Society for Microbiology; and Alexandria, VA: Infectious Diseases Society of America, 2008:713.
15. Koksal I, Yilmaz G, Aksoy F, et al. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever [abstract V-1859]. In: Program and abstracts of the 48th Annual Meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy-Infectious Diseases Society of America (Washington, DC). Washington, DC: American Society for Microbiology; and Alexandria, VA: Infectious Diseases Society of America, 2008:717.
16. Fisgin NT, Doganci L, Ergonul O, Tulek N. Early ribavirin use in Crimean-Congo hemorrhagic fever: significant positive impact in progress [abstract V-1658]. In: Program and abstracts of the 48th Annual Meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy-Infectious Diseases Society of America (Washington, DC). Washington, DC: American Society for Microbiology; and Alexandria, VA: Infectious Diseases Society of America, 2008:714.
17. Shiffman ML. Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors. Clin Liver Dis 2008; 12:487-505.
18. Kumar R, Tripathi P, Baranwal M, Singh S, Tripathi S, Banerjee G. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin Infect Dis 2009; 48:400-6 (in this issue).